A protocol to characterize the morphological changes of Clostridium difficile in response to antibiotic treatment

Journal of Visualized Experiments

Volumn 2017, Issue 123, 2017, Pages

  Endres, Bradley ^a   Bassères, Eugénie ^a   Rashid, Tasnuva ^a   Chang, Long ^a   Alam, M Jahangir ^a   Garey, Kevin W ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Antibiotics; Clostridium difficile; Fidaxomicin; Issue 123; Metronidazole; Ridinilazole; Scanning electron microscopy; Vancomycin

Indexed keywords

ANTIINFECTIVE AGENT; METRONIDAZOLE; VANCOMYCIN;

DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; PEPTOCLOSTRIDIUM DIFFICILE; REPRODUCIBILITY; SCANNING ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; METRONIDAZOLE; MICROSCOPY, ELECTRON, SCANNING; REPRODUCIBILITY OF RESULTS; VANCOMYCIN;

EID: 85025074261     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/55383     Document Type: Article

References (14)

1. Lessa, F. C. et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 372 (9), 825-834 (2015).
2. Vickers, R. J. et al. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. (2016).
3. Shah, D. et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther. 8 (5), 555-564 (2010).
4. Ambrose, P. G. et al. New EMA guideline for antimicrobial development. Lancet Infect Dis. 12 (4), 265-266 (2012).
5. Basseres, E. et al. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. (2016).
6. Endres, B. T. et al. A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile. Anaerobe. 40 10-14 (2016).
7. Endres, B. T. et al. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrob Agents Chemother. 60 (6), 3519-3523 (2016).
8. Alam, M. J., Anu, A., Walk, S. T., & Garey, K. W. Investigation of potentially pathogenic Clostridium difficile contamination in household environs. Anaerobe. 27 31-33 (2014).
9. Aitken, S. L. et al. In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infect Control Hosp Epidemiol. 1-6 (2015).
10. Basseres, E. et al. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. 71 (5), 1245-1251 (2016).
11. Walters, B. A., Roberts, R., Stafford, R., & Seneviratne, E. Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy. Gut. 24 (3), 206-212 (1983).
12. Chilton, C. H. et al. Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery. J Antimicrob Chemother. 68 (9), 2078-2082 (2013).
13. Ofosu, A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol. 29 (2), 147-154 (2016).
14. McDonald, L. C. et al. An epidemic, toxin gene-variant strain of Clostridium difficile. New Eng J Med. 353 (23), 2433-2441 (2005).